Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Chen-Yi Cheung"'
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-15 (2023)
Here using drug susceptibility profiling, genomics and evolutionary studies the authors provide strategies to exploit collateral drug responses in Mycobacterium tuberculosis to prevent the emergence of drug resistance.
Externí odkaz:
https://doaj.org/article/81a3d4b957ed4d498e100c4e55263a4c
Autor:
Nitin Pal Kalia, Samsher Singh, Kiel Hards, Chen-Yi Cheung, Ekaterina Sviriaeva, Amir Banaei-Esfahani, Ruedi Aebersold, Michael Berney, Gregory M. Cook, Kevin Pethe
Publikováno v:
Cell Reports, Vol 42, Iss 5, Pp 112444- (2023)
Summary: The bioenergetic mechanisms by which Mycobacterium tuberculosis survives hypoxia are poorly understood. Current models assume that the bacterium shifts to an alternate electron acceptor or fermentation to maintain membrane potential and ATP
Externí odkaz:
https://doaj.org/article/9d80392a417e4e81ac7c55890f889fb7
Autor:
Kiel Hards, Chen-Yi Cheung, Natalie Waller, Cara Adolph, Laura Keighley, Zhi Shean Tee, Liam K. Harold, Ayana Menorca, Richard S. Bujaroski, Benjamin J. Buckley, Joel D. A. Tyndall, Matthew B. McNeil, Kyu Y. Rhee, Helen K. Opel-Reading, Kurt Krause, Laura Preiss, Julian D. Langer, Thomas Meier, Erik J. Hasenoehrl, Michael Berney, Michael J. Kelso, Gregory M. Cook
Publikováno v:
Communications Biology, Vol 5, Iss 1, Pp 1-11 (2022)
Derivatives of the FDA-approved drug, amiloride, can eliminate drug-resistant Mycobacterium tuberculosis in vitro by interfering with bacterial energy conservation.
Externí odkaz:
https://doaj.org/article/dae3bf53428948ca8c7fbb2eb80c8d45
Autor:
Matthew B. McNeil, Chen-Yi Cheung, Natalie J. E. Waller, Cara Adolph, Cassandra L. Chapman, Noon E. J. Seeto, William Jowsey, Zhengqiu Li, H. M. Adnan Hameed, Tianyu Zhang, Gregory M. Cook
Publikováno v:
Frontiers in Cellular and Infection Microbiology, Vol 12 (2022)
Mycobacterium tuberculosis remains a leading cause of infectious disease morbidity and mortality for which new drug combination therapies are needed. Mycobacterial bioenergetics has emerged as a promising space for the development of novel therapeuti
Externí odkaz:
https://doaj.org/article/ee0242a3a0bb4732ac464a6c58aeb610
Publikováno v:
iScience, Vol 25, Iss 1, Pp 103573- (2022)
Summary: Mycobacterium tuberculosis remains a leading cause of infectious disease morbidity and mortality for which new drug combination therapies are needed. Combinations of respiratory inhibitors can have synergistic or synthetic lethal interaction
Externí odkaz:
https://doaj.org/article/054a63d2c9954e41b9db92c7af305472
Autor:
Scott A. Ferguson, Ayana Menorca, Essie M. Van Zuylen, Chen-Yi Cheung, Michelle A. McConnell, David Rennison, Margaret A. Brimble, Kip Bodle, Scott McDougall, Gregory M. Cook, Adam Heikal
Publikováno v:
Frontiers in Microbiology, Vol 10 (2019)
In this study we investigated the influence of oxygen availability on a phenotypic microtiter screen to identify new, natural product inhibitors of growth for the bovine mastitis-causing microorganisms; Streptococcus uberis, Staphylococcus aureus, an
Externí odkaz:
https://doaj.org/article/f54776368f7c437aacd82039efa04740
Autor:
Mohammad A. M. Momin, Bhamini Rangnekar, Shubhra Sinha, Chen-Yi Cheung, Gregory M. Cook, Shyamal C. Das
Publikováno v:
Pharmaceutics, Vol 11, Iss 10, p 502 (2019)
Bedaquiline is a newly developed anti-tuberculosis drug, conditionally approved by the United States Food and Drug Administration (USFDA) for treating drug-resistant tuberculosis in adults. Oral delivery of bedaquiline causes severe side effects such
Externí odkaz:
https://doaj.org/article/33ff72ed3afb44d5a970dcc4509bba56
Autor:
Elinor Hortle, David I. Roper, Warwick J. Britton, Richard J. Payne, Gregory M. Cook, Wendy Tran, Paige M. E. Hawkins, Alexander Stoye, Christopher G. Dowson, Rebecca E Audette, Thomas Balle, Jessica L. Ochoa, Gayathri Nagalingam, Daniel J Ford, Ali Saad Kusay, Venugopal Pujari, Roger G. Linington, Chen-Yi Cheung, Dean C. Crick, Eric J. Rubin, Stefan H. Oehlers, Susan A. Charman
Publikováno v:
Journal of Medicinal Chemistry. 64:17326-17345
Herein, we report the design and synthesis of inhibitors of Mycobacterium tuberculosis (Mtb) phospho-MurNAc-pentapeptide translocase I (MurX), the first membrane-associated step of peptidoglycan synthesis, leveraging the privileged structure of the s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4e08cda86f6791396aa219a030366f02
https://doi.org/10.1021/acs.jmedchem.1c01407
https://doi.org/10.1021/acs.jmedchem.1c01407
The increasing incidence of drug resistance inMycobacterium tuberculosishas diminished the efficacy of almost all available antibiotics, complicating efforts to combat the spread of this global health burden. Alongside the development of new drugs, o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::11c65dd2b5178e833286e6c9f42bcf0b
https://doi.org/10.1101/2022.10.31.514625
https://doi.org/10.1101/2022.10.31.514625
Autor:
Al-Zubaidi A, Stephanie S. Dawes, Gregory M. Cook, Lott Js, Mizrahi, George Taiaroa, Chen-Yi Cheung
Publikováno v:
Antimicrob Agents Chemother
Multidrug resistant (MDR) tuberculosis (TB) is defined by the resistance of Mycobacterium tuberculosis, the causative organism, to the first-line antibiotics rifampicin and isoniazid. Mitigating or reversing resistance to these drugs offers a means o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42d42f68b387e9e3fa365647c9658903
https://doi.org/10.1128/aac.02091-21
https://doi.org/10.1128/aac.02091-21